The obesity pipeline: current strategies in the development of anti-obesity drugs.
This review provides a summary of currently available pharmaceutical therapies for the treatment of obesity, along with an overview of the pipeline of products currently in development, and the key mechanisms on which the major development candidates are based. In particular, the recent increase in understanding of the role of gut peptides in energy homeostasis is highlighted as a promising source of potential future obesity therapies.
Cooke
Dunstan
D
Thiakis Limited, Imperial BioIncubator, Bessemer Building (RSM), Prince Consort Road, London SW7 2BP, UK.
Bloom
Steve
S
D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002490:Central Nervous System / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005768:Gastrointestinal Hormones / Q000037:antagonists & inhibitors / Q000502:physiology; D006801:Humans; D008049:Lipase / Q000037:antagonists & inhibitors; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects
D019440:Anti-Obesity Agents; D004791:Enzyme Inhibitors; D005768:Gastrointestinal Hormones; D043884:Receptor, Cannabinoid, CB1; D008049:Lipase